| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
55,671,000 |
| Market
Cap: |
78.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.2 - $11.21 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Marinus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for patients suffering from rare genetic epilepsies and other seizure disorders. The U.S Food and Drug Administration approved the use of ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two years of age and older. Ganaxolone is being developed in formulations for various routes of administration: intravenous and oral. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,803 |
21,803 |
38,528 |
41,369 |
| Total Sell Value |
$215,409 |
$215,409 |
$374,962 |
$393,504 |
| Total People Sold |
5 |
5 |
5 |
8 |
| Total Sell Transactions |
5 |
5 |
15 |
18 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Braunstein Scott |
CHAIRMAN AND CEO |
• • – |
2023-08-07 |
4 |
AS |
$9.55 |
$61,244 |
D/D |
(6,413) |
160,792 |
|
-4% |
|
| Pfanstiel Steven |
CFO AND COO |
• – – |
2023-08-07 |
4 |
AS |
$9.54 |
$26,617 |
D/D |
(2,790) |
49,338 |
|
-4% |
|
| Hulihan Joseph |
CHIEF MEDICAL OFFICER |
• – – |
2023-08-07 |
4 |
AS |
$9.55 |
$27,590 |
D/D |
(2,889) |
47,627 |
|
-4% |
|
| Manning Martha E |
SVP, GEN. COUNSEL & CORP. SEC. |
• – – |
2023-08-07 |
4 |
AS |
$9.54 |
$20,692 |
D/D |
(2,169) |
33,036 |
|
-4% |
|
| Noonberg Sarah B. |
|
– • – |
2023-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
7,200 |
|
- |
|
| Johnson Marvin |
|
– • – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
7,200 |
|
- |
|
| Austin Charles |
|
– • – |
2023-02-06 |
4 |
AS |
$6.49 |
$6,964 |
D/D |
(1,073) |
5,277 |
|
51% |
|
| Fischer Seth H.z. |
|
– • – |
2023-02-06 |
4 |
AS |
$6.54 |
$6,658 |
D/D |
(1,018) |
6,026 |
|
51% |
|
| Ezickson Elan |
|
– • – |
2023-02-06 |
4 |
AS |
$6.56 |
$4,920 |
D/D |
(750) |
5,600 |
|
51% |
|
| Shafer Christina |
CHIEF COMMERCIAL OFFICER |
• – – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
17,375 |
43,022 |
|
- |
|
| Nochur Sara |
|
– • – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
6,350 |
|
- |
|
| Manning Martha E |
VP, GEN. COUNSEL & CORP. SEC. |
• – – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
16,548 |
35,205 |
|
- |
|
| Hulihan Joseph |
CHIEF MEDICAL OFFICER |
• – – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
25,648 |
50,516 |
|
- |
|
| Braunstein Scott |
CHAIRMAN AND CEO |
• • – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
167,205 |
|
- |
|
| Fischer Seth H.z. |
|
– • – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
7,044 |
|
- |
|
| Pfanstiel Steven |
CHIEF FINANCIAL OFFICER |
• – – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
28,130 |
52,128 |
|
- |
|
| Ezickson Elan |
|
– • – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
6,350 |
|
- |
|
| Mayleben Timothy M |
|
– • – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
17,475 |
|
- |
|
| Silverstein Christine Berni |
|
– • – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
7,200 |
|
- |
|
| Austin Charles |
|
– • – |
2023-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
6,350 |
|
- |
|
| Shafer Christina |
Chief Commercial Officer |
• – – |
2022-11-09 |
4 |
D |
$4.70 |
$7,074 |
D/D |
(1,505) |
25,647 |
|
- |
|
| Shafer Christina |
Chief Commercial OfficerOffice |
• – – |
2022-06-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,152 |
|
12% |
|
| Manning Martha E |
VP Gen Counsel and Corp Sec. |
• – – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,790 |
18,657 |
|
- |
|
| Pfanstiel Steven |
Chief Financial Officer |
• – – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
7,448 |
23,998 |
|
- |
|
| Braunstein Scott |
Chairman and CEO |
• • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
19,305 |
87,205 |
|
- |
|
129 Records found
|
|
Page 2 of 6 |
|
|
0.01 (1.06%) 
